The latest in precision prevention news, curated for CancerIQ's community of oncologists, genetic counselors, breast centers, primary care providers, and anyone interested in staying ahead of cancer.
- Almost half of cancer deaths globally are attributable to preventable risk factors, new study suggests via CNN
"These findings highlight that a substantial proportion of cancer burden globally has potential for prevention through interventions aimed at reducing exposure to known cancer risk factors but also that a large proportion of cancer burden might not be avoidable through control of the risk factors currently estimated ... Thus, cancer risk reduction efforts must be coupled with comprehensive cancer control strategies that include efforts to support early diagnosis and effective treatment."
Precision prevention is "the only way forward" when it comes to reducing cancer deaths at the local level, too. While patients can take steps to mitigate their individual risk, providers and health systems can intervene with personalized care plans to stay ahead of cancer. To not only assess each patients' unique risks from genomics to lifestyle factors at scale – but then manage their preventative care over time, providers can look to solutions like CancerIQ.
- Population Genetic Testing: Save Lives And Money, While Avoiding Financial Toxicity via Forbes
"Population testing may help people avoid serious diseases and death, which is a worthy goal for patients, employers, payers and our population at large. But if we support this testing ... it is essential that we carve pathways for participants, to ensure that they are both covered and supported by their insurers, clinicians, and employers throughout this lifetime journey."
CancerIQ is the only precision prevention platform available that enables population testing end-to-end – supporting providers to not only detect but manage resulting personalized care plans over time at scale.
- New ‘Parp inhibitors’ could prevent certain tumours appearing via The Guardian
"Increasing use of PARP inhibitors has raised hopes that many individuals susceptible to certain familial cancers can be treated simply and effectively in coming years. Indeed, it may be possible one day to use PARP inhibitors not just to treat patients after cancers appear but to prevent them from developing at all."
As precision oncology services extend into preventive opportunities, providers can already tap into the opportunity to detect cancer earlier, or stay ahead of it altogether by scaling genetics screenings. With personalized care plans based on hereditary risk, patients benefit from the multitude of existing preventive services and therapies on the market today – and will be the first in line for those still on the way.
Patient navigation improves outcomes and addresses health equity across the cancer continuum via The Cancer Letter“The main drivers of differences in cancer survival are not related to biology; instead, they derive from structural barriers to accessing care and overt documented differences in the delivery of evidence-based care. Patient navigation can facilitate improved health care access and quality for underserved populations through advocacy and care coordination.”
Congratulations to some of our health system partners awarded multi-year grants for patient navigation programs! CancerIQ partners with programs like these, in oncology and beyond, to implement stronger navigation pathways for patients at average and high-risk through both our software and services offerings. By centralizing care navigation, our partners see increased coordination of high-risk services, effectively managing and reducing care gaps, and ultimately capturing otherwise missed downstream revenue.
- Risk-Adapted Screening for CRC Comparable to Established Strategies via MedPage Today
Prioritizing and personalizing the care of the most high-risk patients is not only life-saving, this new study demonstrates that a "'risk-adapted approach is feasible, effective, and cost-favorable' ... Current [colorectal cancer screening] guidelines incorporate a 'one-size-fits-all' age-based approach recommending colonoscopy every 10 years and FIT annually or every other year. However, this strategy does come with drawbacks, such as low adherence, which can be attributed to barriers to or disparities in screening."
CancerIQ is powering at-scale personalized care plans for individuals at the highest risk of hereditary cancers. Our software's risk assessment and stratification tools help providers manage their patients' screenings for the best chance at early detection and precision cancer prevention – in colorectal cancer and beyond.
- Cutting Into Breast Cancer Disparities With Genetic Testing via EverydayHealth
Dr. Olufunmilayo I Olopade's vision for the future of genomics is fundamental to CancerIQ's founding story and mission. This feature from Everyday Health and spotlight from our investors at McKesson Ventures offers a deeper look into her pioneering work.
"If we could evaluate everyone’s genetic profile, we could catch the disease as early as possible instead of waiting for people to become ill. Any cancer is potentially curable if discovered early enough. But right now, too many people don’t know that genetic tests are available, too few doctors ask for them, and insurance often denies coverage. Without solving those problems, we can’t take full advantage of the power of precision medicine."
Don't wait until the end of the month for stories like these. Stay up-to-date with the latest in precision prevention news. Follow CancerIQ on social media to be the first to see our curated content on cancer prevention, precision medicine & oncology, health equity, and more.
Follow Cancer IQ on Social Media